Previous 10 | Next 10 |
CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in two...
Constellation Pharmaceuticals (NASDAQ: CNST ): Q2 GAAP EPS of -$0.80 beats by $0.01 . More news on: Constellation Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Data presented at ASCO and EHA suggest potential disease-modifying activity of CPI-0610 across the spectrum of myelofibrosis (MF) parameters, with multiple potential pathways for approval The EZH2 franchise continues to advance: the ProSTAR study of CPI-1205 remains on track, and the ...
Gainers: Infrastructure and Energy Alternatives (NASDAQ: IEA ) +47% . SSLJ.com (YGTY) +23% . Emmis Communications Corporation (NASDAQ: EMMS ) +24% . Pioneer Power Solutions (NASDAQ: PPSI ) +17% . Seadrill (NYSE: SDRL ) +17% . Ovid Therapeutics (NASDAQ: OVID ) +15% . NeoPhotonic...
Gainers: Infrastructure and Energy Alternatives (NASDAQ: IEA ) +47% . SSLJ.com (YGTY) +23% . Emmis Communications Corporation (NASDAQ: EMMS ) +24% . Pioneer Power Solutions (NASDAQ: PPSI ) +17% . Seadrill (NYSE: SDRL ) +17% . Ovid Therapeutics (NASDAQ: OVID ) +15% . NeoPhotonic...
CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present ...
CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST) today announced that Dr. Jacob Stuckey, Senior Scientist at Constellation Pharmaceuticals, gave an oral presentation titled Methods for Kinetic Assessment of High Affinity EZH2 I...
CPI-0610 showed signals of clinical activity, both as a monotherapy and in combination with ruxolitinib, in refractory myelofibrosis (MF) patients Patients treated with CPI-0610 exhibited improvement in spleen volume, constitutional symptoms, anemia, bone marrow fibrosis, and transfusi...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees Apple (AAPL) host its annual WWDC conference, Walmart (WMT) hol...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Constellation Pharmaceuticals Inc. Website:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...